Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network
Arthur Petat, Eric Dansin, Fabien Calcagno, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
Martin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Benjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
Joel Neal, Nick Pavlakis, Sang-We Kim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
Simon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Journal for Immunotherapy of Cancer
|
May 31, 2023
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, et al.
The Journal of Clinical Investigation
|
November 1, 2019
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Emilie Bousquet Mur, Sara Bernardo, Laura Papon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
EMBO Molecular Medicine
|
January 16, 2026
NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum
Sara Bernardo, Lisa Brunet, Quentin Dominique Thomas, et al.
The New England Journal of Medicine
|
September 9, 2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network
Arthur Petat, Eric Dansin, Fabien Calcagno, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
Martin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Benjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
Joel Neal, Nick Pavlakis, Sang-We Kim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
Simon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Journal for Immunotherapy of Cancer
|
May 31, 2023
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, et al.
The Journal of Clinical Investigation
|
November 1, 2019
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Emilie Bousquet Mur, Sara Bernardo, Laura Papon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
EMBO Molecular Medicine
|
January 16, 2026
NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum
Sara Bernardo, Lisa Brunet, Quentin Dominique Thomas, et al.
The New England Journal of Medicine
|
September 9, 2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Page
of 9